As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a ...

According to Boehringer, Hernexeos achieved a 77% objective response rate (OOR) in a cohort of previously untreated HER2+ NSCLC patients in Beamion Lung-1, with 8% complete responses and 69% partial ...

Millions of women worldwide live with endometriosis, which causes symptoms like pain and extreme tiredness and, if untreated, ...

Researchers in the UK have started recruiting patients for a large-scale trial that will test a battery of Parkinson's ...

Reimbursement authority NICE has said that Apretude (cabotegravir) can now be used as an alternative to daily oral PrEP pills ...

On Friday 17th October, the European Society for Medical Oncology’s Annual Meeting 2025 kicked off, with the opening press ...

The results – presented at the ESMO cancer congress and simultaneously published in Annals of Oncology – come after seven ...

The FDA has named the first products to take advantage of its recently announced Commissioner's national priority voucher ...

Debruyne has said that in recent years Bavarian Nordic has received several enquiries about a takeover but has never actively ...

Interestingly, while only 16% of oncology researchers reported using AI in biomarker detection and assessment at the time of ...

Moreover, innovations in LNP formulations have improved not only their targeting ability, but also their drug-loading ...

AstraZeneca has become the second pharma group, after Pfizer, to reach an agreement with the Trump administration on a deal ...